Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Groupe Francophone des Myelodysplasies · NCT06956755
This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6990 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Groupe Francophone des Myelodysplasies (other) |
| Locations | 1 site (Rouen) |
| Trial ID | NCT06956755 on ClinicalTrials.gov |
What this trial studies
This ongoing observational registry collects longitudinal data on patients diagnosed with myelodysplastic syndromes (MDS) and therapy-related acute myeloid leukemia (t-AML). It gathers comprehensive information including demographics, clinical parameters, and health care interventions from participants over 18 years of age. The registry, initiated in 2003, operates under strict ethical guidelines and ensures patient anonymity while recording vital health data. It aims to enhance understanding of these conditions and improve patient care through detailed data collection.
Who should consider this trial
Good fit: Ideal candidates for this registry are adults over 18 years diagnosed with myelodysplastic syndromes or therapy-related acute myeloid leukemia.
Not a fit: Patients under 18 years or those unwilling to provide consent will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with MDS and t-AML.
How similar studies have performed: Other observational studies have shown success in collecting valuable data for similar conditions, indicating that this approach is both tested and beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female * Age \> 18 years * Patients with myelodysplastic syndrome and therapy-related acute myeloid leukemia * Able and willing to provide written informed consent Exclusion Criteria: * Age \<18 years * Patient is unwilling or unable to give consent
Where this trial is running
Rouen
- Aspasia Stamatoullas — Rouen, France (RECRUITING)
Study contacts
- Study coordinator: Fatiha CHERMAT, PhD
- Email: fatiha.chermat-ext@aphp.fr
- Phone: +33(0)1 71 20 70 59
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, MDS, t-AML